{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-070337","form_type":"8-K","ticker":"LCTX","cik":"0000876343","company_name":"Lineage Cell Therapeutics, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.547891+00:00","generated_at":"2026-05-21T19:44:41.450440+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Lineage Cell Therapeutics Q1 2025 net loss narrows to $4.1M; cash runway into Q1 2027","bullets":["Net loss attributable of $4.1M ($0.02/shr) vs $6.5M ($0.04/shr) in Q1 2024; revenue $1.5M (flat YoY).","Cash and marketable securities of $47.9M as of Mar 31, 2025 expected to fund operations into Q1 2027.","OpRegen 36-month data to be presented June 21 at CTS 2025; OPC1 DOSED study initiated Feb 2025 for spinal cord injury.","3rd Annual SCI Investor Symposium announced with Christopher & Dana Reeve Foundation, virtual starting June 27, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-070337","json":"https://secwatch.observer/filing/0000950170-25-070337.json","markdown":"https://secwatch.observer/filing/0000950170-25-070337.md","text":"https://secwatch.observer/filing/0000950170-25-070337.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876343/000095017025070337/0000950170-25-070337-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876343/000095017025070337/lctx-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T19:44:41.450440+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}